Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 adjuvant therapy versus placebo in poor-risk DLBCL after complete response to first-line rituximab-chemotherapy
2008-000498-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Everolimus adjuvant therapy with Matching placebo (2 arms). Primary endpoint: Disease-free survival. Started Apr 2009; status: completed.
02
Drugs
everolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2008-000498-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000498-40.